The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants.

Autor: Rothenberger S; Spiez Laboratory, Austrasse, Spiez, Switzerland.; Institute of Microbiology, University Hospital Center and University of Lausanne, Lausanne, Switzerland., Hurdiss DL; Department Biomolecular Health Sciences, Division Infectious Diseases & Immunology - Virology section, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands.; Cryo-Electron Microscopy, Bijvoet Center for Biomolecular Research, Department of Chemistry, Faculty of Science, Utrecht University, Utrecht, Netherlands., Walser M; Molecular Partners AG, Zurich-Schlieren, Switzerland., Malvezzi F; Molecular Partners AG, Zurich-Schlieren, Switzerland., Mayor J; Spiez Laboratory, Austrasse, Spiez, Switzerland.; Institute of Microbiology, University Hospital Center and University of Lausanne, Lausanne, Switzerland., Ryter S; Spiez Laboratory, Austrasse, Spiez, Switzerland., Moreno H; Institute of Microbiology, University Hospital Center and University of Lausanne, Lausanne, Switzerland., Liechti N; Spiez Laboratory, Austrasse, Spiez, Switzerland., Bosshart A; Molecular Partners AG, Zurich-Schlieren, Switzerland., Iss C; Molecular Partners AG, Zurich-Schlieren, Switzerland., Calabro V; Molecular Partners AG, Zurich-Schlieren, Switzerland., Cornelius A; Molecular Partners AG, Zurich-Schlieren, Switzerland., Hospodarsch T; Molecular Partners AG, Zurich-Schlieren, Switzerland., Neculcea A; Molecular Partners AG, Zurich-Schlieren, Switzerland., Looser T; Molecular Partners AG, Zurich-Schlieren, Switzerland., Schlegel A; Molecular Partners AG, Zurich-Schlieren, Switzerland., Fontaine S; Molecular Partners AG, Zurich-Schlieren, Switzerland., Villemagne D; Molecular Partners AG, Zurich-Schlieren, Switzerland., Paladino M; Molecular Partners AG, Zurich-Schlieren, Switzerland., Schiegg D; Molecular Partners AG, Zurich-Schlieren, Switzerland., Mangold S; Molecular Partners AG, Zurich-Schlieren, Switzerland., Reichen C; Molecular Partners AG, Zurich-Schlieren, Switzerland., Radom F; Molecular Partners AG, Zurich-Schlieren, Switzerland., Kaufmann Y; Molecular Partners AG, Zurich-Schlieren, Switzerland., Schaible D; Molecular Partners AG, Zurich-Schlieren, Switzerland., Schlegel I; Molecular Partners AG, Zurich-Schlieren, Switzerland., Zitt C; Molecular Partners AG, Zurich-Schlieren, Switzerland., Sigrist G; Molecular Partners AG, Zurich-Schlieren, Switzerland., Straumann M; Molecular Partners AG, Zurich-Schlieren, Switzerland., Wolter J; Molecular Partners AG, Zurich-Schlieren, Switzerland., Comby M; Molecular Partners AG, Zurich-Schlieren, Switzerland., Sacarcelik F; Molecular Partners AG, Zurich-Schlieren, Switzerland., Drulyte I; Materials and Structural Analysis, Thermo Fisher Scientific, Eindhoven, Netherlands., Lyoo H; Department Biomolecular Health Sciences, Division Infectious Diseases & Immunology - Virology section, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands., Wang C; Department Biomolecular Health Sciences, Division Infectious Diseases & Immunology - Virology section, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands., Li W; Department Biomolecular Health Sciences, Division Infectious Diseases & Immunology - Virology section, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands., Du W; Department Biomolecular Health Sciences, Division Infectious Diseases & Immunology - Virology section, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands., Binz HK; Binz Biotech Consulting, Zug, Switzerland., Herrup R; Laboratory of Immunoregulation, Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA., Lusvarghi S; Laboratory of Immunoregulation, Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA., Neerukonda SN; Laboratory of Immunoregulation, Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA., Vassell R; Laboratory of Immunoregulation, Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA., Wang W; Laboratory of Immunoregulation, Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA., Adler JM; Freie Universität Berlin, Institut für Virologie, Berlin, Germany., Eschke K; Freie Universität Berlin, Institut für Virologie, Berlin, Germany., Nascimento M; Freie Universität Berlin, Institut für Virologie, Berlin, Germany., Abdelgawad A; Freie Universität Berlin, Institut für Virologie, Berlin, Germany., Gruber AD; Freie Universität Berlin, Institut für Tierpathologie, Berlin, Germany., Bushe J; Freie Universität Berlin, Institut für Tierpathologie, Berlin, Germany., Kershaw O; Freie Universität Berlin, Institut für Tierpathologie, Berlin, Germany., Knutson CG; Novartis Institutes for BioMedical Research, PK Sciences, Cambridge, MA, USA., Balavenkatraman KK; Novartis Institutes for BioMedical Research, Preclinical Safety, Basel, Switzerland., Ramanathan K; Novartis Pharma AG, Basel, Switzerland., Wyler E; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Teixeira Alves LG; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Lewis S; Molecular Partners AG, Zurich-Schlieren, Switzerland., Watson R; Molecular Partners AG, Zurich-Schlieren, Switzerland., Haeuptle MA; Molecular Partners AG, Zurich-Schlieren, Switzerland., Zürcher A; Molecular Partners AG, Zurich-Schlieren, Switzerland., Dawson KM; Molecular Partners AG, Zurich-Schlieren, Switzerland., Steiner D; Molecular Partners AG, Zurich-Schlieren, Switzerland., Weiss CD; Laboratory of Immunoregulation, Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA., Amstutz P; Molecular Partners AG, Zurich-Schlieren, Switzerland., van Kuppeveld FJM; Department Biomolecular Health Sciences, Division Infectious Diseases & Immunology - Virology section, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands., Stumpp MT; Molecular Partners AG, Zurich-Schlieren, Switzerland. info@molecularpartners.com., Bosch BJ; Department Biomolecular Health Sciences, Division Infectious Diseases & Immunology - Virology section, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands., Engler O; Spiez Laboratory, Austrasse, Spiez, Switzerland., Trimpert J; Freie Universität Berlin, Institut für Virologie, Berlin, Germany.

Publikováno v: Nature biotechnology [Nat Biotechnol] 2022 Dec; Vol. 40 (12), pp. 1845-1854. Date of Electronic Publication: 2022 Jul 21.

Characterization and immunogenicity of a Shigella flexneri 2a O-antigen bioconjugate vaccine candidate.

Autor: Ravenscroft N; Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa., Braun M; LimmaTech Biologics AG, Grabenstrasse 3, 8952 Schlieren, Switzerland., Schneider J; LimmaTech Biologics AG, Grabenstrasse 3, 8952 Schlieren, Switzerland., Dreyer AM; LimmaTech Biologics AG, Grabenstrasse 3, 8952 Schlieren, Switzerland., Wetter M; LimmaTech Biologics AG, Grabenstrasse 3, 8952 Schlieren, Switzerland., Haeuptle MA; LimmaTech Biologics AG, Grabenstrasse 3, 8952 Schlieren, Switzerland., Kemmler S; LimmaTech Biologics AG, Grabenstrasse 3, 8952 Schlieren, Switzerland., Steffen M; LimmaTech Biologics AG, Grabenstrasse 3, 8952 Schlieren, Switzerland., Sirena D; LimmaTech Biologics AG, Grabenstrasse 3, 8952 Schlieren, Switzerland., Herwig S; LimmaTech Biologics AG, Grabenstrasse 3, 8952 Schlieren, Switzerland., Carranza P; LimmaTech Biologics AG, Grabenstrasse 3, 8952 Schlieren, Switzerland., Jones C; Department of Paediatrics, University of Oxford, Oxford OX3 9DU, United Kingdom., Pollard AJ; Department of Paediatrics, University of Oxford, Oxford OX3 9DU, United Kingdom., Wacker M; LimmaTech Biologics AG, Grabenstrasse 3, 8952 Schlieren, Switzerland.; Wacker Biotech Consulting AG, Obere Hönggerstrasse 9a, 8103 Unterengstringen, Switzerland., Kowarik M; LimmaTech Biologics AG, Grabenstrasse 3, 8952 Schlieren, Switzerland.

Publikováno v: Glycobiology [Glycobiology] 2019 Aug 20; Vol. 29 (9), pp. 669-680.

Immunogenicity and safety of a tetravalent E. coli O-antigen bioconjugate vaccine in animal models.

Autor: van den Dobbelsteen GPJM; Bacterial Vaccines Discovery & Early Development, Janssen Vaccines and Prevention B.V. (former Crucell Holland B.V.), Part of the Janssen Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 4-6, 2333CN Leiden, The Netherlands. Electronic address: gdobbel@its.jnj.com., Faé KC; Bacterial Vaccines Discovery & Early Development, Janssen Vaccines and Prevention B.V. (former Crucell Holland B.V.), Part of the Janssen Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 4-6, 2333CN Leiden, The Netherlands. Electronic address: kfae@its.jnj.com., Serroyen J; Bacterial Vaccines Discovery & Early Development, Janssen Vaccines and Prevention B.V. (former Crucell Holland B.V.), Part of the Janssen Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 4-6, 2333CN Leiden, The Netherlands. Electronic address: jserroy1@its.jnj.com., van den Nieuwenhof IM; Bacterial Vaccines Discovery & Early Development, Janssen Vaccines and Prevention B.V. (former Crucell Holland B.V.), Part of the Janssen Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 4-6, 2333CN Leiden, The Netherlands. Electronic address: Ivanden@its.jnj.com., Braun M; LimmaTech Biologics (former GlycoVaxyn AG), Grabenstrasse 3, 8952 Schlieren, Switzerland. Electronic address: Martin.Braun@lmtbio.com., Haeuptle MA; LimmaTech Biologics (former GlycoVaxyn AG), Grabenstrasse 3, 8952 Schlieren, Switzerland; Current address: Molecular Partners AG, Wagistrasse 14, 8952 Zürich-Schlieren, Switzerland. Electronic address: Micha.Haeuptle@molecularpartners.com., Sirena D; LimmaTech Biologics (former GlycoVaxyn AG), Grabenstrasse 3, 8952 Schlieren, Switzerland. Electronic address: Dominique.Sirena@lmtbio.com., Schneider J; LimmaTech Biologics (former GlycoVaxyn AG), Grabenstrasse 3, 8952 Schlieren, Switzerland. Electronic address: Joerg.Schneider@lmtbio.com., Alaimo C; LimmaTech Biologics (former GlycoVaxyn AG), Grabenstrasse 3, 8952 Schlieren, Switzerland. Electronic address: Cristina.Alaimo@lmtbio.com., Lipowsky G; LimmaTech Biologics (former GlycoVaxyn AG), Grabenstrasse 3, 8952 Schlieren, Switzerland. Electronic address: Gerd.Lipowsky@lmtbio.com., Gambillara-Fonck V; LimmaTech Biologics (former GlycoVaxyn AG), Grabenstrasse 3, 8952 Schlieren, Switzerland. Electronic address: Veronica.Gambillara@lmtbio.com., Wacker M; LimmaTech Biologics (former GlycoVaxyn AG), Grabenstrasse 3, 8952 Schlieren, Switzerland; Current address: Wacker Biotech Consulting, Obere Hönggerstrasse 9a, 8103 Unterengstringen, Switzerland. Electronic address: Michael.Wacker@wbioc.com., Poolman JT; Bacterial Vaccines Discovery & Early Development, Janssen Vaccines and Prevention B.V. (former Crucell Holland B.V.), Part of the Janssen Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 4-6, 2333CN Leiden, The Netherlands. Electronic address: JPoolman@its.jnj.com.

Publikováno v: Vaccine [Vaccine] 2016 Jul 29; Vol. 34 (35), pp. 4152-4160. Date of Electronic Publication: 2016 Jul 06.

Improvement of dolichol-linked oligosaccharide biosynthesis by the squalene synthase inhibitor zaragozic acid.

Autor: Haeuptle MA; Institute of Physiology, University of Zürich, CH-8057 Zürich, Switzerland., Welti M, Troxler H, Hülsmeier AJ, Imbach T, Hennet T

Publikováno v: The Journal of biological chemistry [J Biol Chem] 2011 Feb 25; Vol. 286 (8), pp. 6085-91. Date of Electronic Publication: 2010 Dec 23.

RFT1-CDG: deafness as a novel feature of congenital disorders of glycosylation.

Autor: Jaeken J; Center for Metabolic Disease, University of Leuven, Leuven, Belgium. jaak.jaeken@uzleuven.be, Vleugels W, Régal L, Corchia C, Goemans N, Haeuptle MA, Foulquier F, Hennet T, Matthijs G, Dionisi-Vici C

Publikováno v: Journal of inherited metabolic disease [J Inherit Metab Dis] 2009 Dec; Vol. 32 Suppl 1, pp. S335-8. Date of Electronic Publication: 2009 Oct 24.